As a selective inhibitor of KLF5, ML264 exhibits potent antitumor activity in multiple preclinical models including colorectal and ovarian cancers, and possesses favorable pharmacokinetic properties with promising safety for KLF5-targeted therapeutic strategies [23, 24]. This evidence concerns the gene KLF5 and ovarian cancer.